What Is Quercetin

Quercetin is a flavonoid, a class of polyphenolic compounds, found widely in plant foods including onions, apples, berries, capers, and green tea. It functions as both an antioxidant and a senolytic agent, meaning it can neutralize reactive oxygen species while also selectively inducing death in damaged, aging cells. Quercetin is one of the most abundant dietary flavonoids and has become a focal point in longevity research due to its involvement in multiple pathways associated with cellular aging.

Aging is accompanied by two closely related problems: the accumulation of oxidative damage and the buildup of senescent cells. Senescent cells are cells that have stopped dividing but refuse to die, instead secreting a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype (SASP). This secretory activity contributes to chronic low-grade inflammation, tissue dysfunction, and the progression of age-related diseases. Quercetin sits at the intersection of these processes because it addresses both oxidative stress and senescent cell burden.

From a longevity perspective, quercetin's senolytic properties have attracted the most attention. Preclinical work pairing quercetin with dasatinib showed that clearing senescent cells improved physical function, extended healthspan, and, in some mouse models, extended lifespan. Even as a standalone compound, quercetin modulates NF-kB signaling, inhibits pro-inflammatory cytokine production, and stabilizes mast cells, all of which contribute to the broader goal of reducing the inflammatory load that accelerates biological aging.

Quercetin's antioxidant activity stems from its molecular structure. The arrangement of hydroxyl groups on its flavonoid backbone allows it to donate electrons to free radicals, neutralizing reactive oxygen species before they damage lipids, proteins, and DNA. It also upregulates endogenous antioxidant enzymes, including superoxide dismutase and catalase, through activation of the Nrf2 pathway, a master regulator of the cellular antioxidant response.

As a senolytic, quercetin works by interfering with the pro-survival networks that senescent cells depend on to avoid apoptosis. Senescent cells upregulate anti-apoptotic proteins such as Bcl-2 family members. Quercetin inhibits several of these survival pathways, including PI3K/Akt signaling, tipping senescent cells past the threshold where they can no longer resist programmed cell death. This effect is cell-type specific; quercetin appears particularly active against senescent endothelial cells and certain progenitor populations, which is why combination with dasatinib (which targets different cell types) is used to broaden the senolytic reach.

Beyond these two primary mechanisms, quercetin inhibits the enzyme lipoxygenase and suppresses NF-kB translocation to the nucleus, reducing the transcription of pro-inflammatory genes. It also stabilizes mast cell membranes, reducing histamine release. These anti-inflammatory and antihistamine effects are mechanistically distinct from its antioxidant or senolytic roles and help explain why quercetin appears in such a wide range of clinical contexts, from allergy management to cardiovascular research.

Quercetin is available in several supplemental forms, and the choice of form significantly affects how much of the compound reaches systemic circulation. Standard quercetin dihydrate or quercetin anhydrous powders have low oral bioavailability, estimated at roughly 2% in some pharmacokinetic studies, due to poor water solubility and extensive first-pass metabolism in the gut and liver.

Phytosomal formulations, which encapsulate quercetin in a phospholipid complex (often sunflower lecithin), have shown substantially improved absorption in comparative pharmacokinetic studies. Liposomal quercetin uses a similar lipid-encapsulation strategy. Another common approach is combining quercetin with bromelain, a pineapple-derived enzyme mixture that may enhance absorption and has its own anti-inflammatory properties. Some products add vitamin C, which stabilizes quercetin in the gut and may improve uptake. Quercetin glycoside forms, such as isoquercetin (quercetin-3-O-glucoside), are more water-soluble than the aglycone and demonstrate faster, more complete absorption in direct comparisons.

For individuals specifically interested in senolytic applications, the form matters because achieving higher transient plasma concentrations is likely more relevant than maintaining low steady-state levels. Phytosomal or isoquercetin forms are generally better suited to this goal than standard quercetin powder.

Dosing quercetin depends on the intended application. For general antioxidant and anti-inflammatory support, most human trials have used 500 to 1,000 milligrams daily, typically split into two doses taken with meals containing dietary fat. At these doses, standard quercetin formulations produce measurable but modest plasma levels, while phytosomal or isoquercetin forms achieve higher concentrations.

For senolytic protocols inspired by preclinical research, intermittent high-dose approaches are more common. The dasatinib-plus-quercetin regimen used in published pilot trials typically employed quercetin at 1,000 milligrams daily for three consecutive days, repeated at intervals of one to four weeks. Those using quercetin alone for senolytic purposes sometimes adopt a similar intermittent pattern, though the evidence supporting quercetin monotherapy as a senolytic in humans is limited.

Taking quercetin on an empty stomach results in poor absorption. Co-administration with fat, bromelain, or vitamin C is a practical step to improve uptake regardless of the specific formulation chosen.

When evaluating quercetin supplements, third-party testing certification is a basic quality indicator. Look for products verified by organizations such as NSF International, USP, or Informed Sport, which test for identity, potency, and contaminant levels including heavy metals, pesticides, and microbial contamination.

The label should clearly identify the specific form of quercetin used: quercetin dihydrate, quercetin anhydrous, quercetin phytosome, or isoquercetin. Products that list only "quercetin" without specifying the form make it difficult to assess expected bioavailability. For phytosomal formulations, look for branded complexes with published pharmacokinetic data. The source material should also be disclosed; most supplemental quercetin is derived from the flower buds of Sophora japonica (Japanese pagoda tree) or from onion skin extract.

Avoid products with excessive fillers, artificial colorants, or proprietary blends that obscure the actual quercetin dose. If bromelain is included, its activity should be listed in GDU (gelatin digesting units) rather than just milligrams, as enzymatic potency varies independently of weight.

The strongest preclinical evidence for quercetin involves its senolytic effects when combined with dasatinib. Multiple animal studies have shown that this combination clears senescent cells, improves physical function, reduces markers of frailty, and extends healthspan in aged mice. Some of these studies also demonstrated modest lifespan extension. A small number of pilot human trials have tested dasatinib plus quercetin in conditions such as idiopathic pulmonary fibrosis and diabetic kidney disease, finding reductions in senescent cell markers and SASP-related cytokines. These trials were early-phase, with small sample sizes and short durations.

For quercetin as a standalone supplement, the human evidence is broader but more diffuse. Randomized controlled trials have examined its effects on blood pressure, inflammatory markers, exercise performance, and upper respiratory infection incidence in athletes. Results are mixed: some trials show modest reductions in blood pressure and CRP in hypertensive populations, while others find no significant differences from placebo. Bioavailability remains a consistent limitation in human research, as standard quercetin formulations have poor absorption. Newer phytosomal and liposomal delivery formats have improved this, but many older studies used conventional forms, which may underestimate the compound's potential. Large, long-duration trials focused specifically on aging outcomes are still lacking.

Quercetin is generally well tolerated at doses up to 1,000 milligrams daily in studies lasting several months. It can inhibit cytochrome P450 enzymes (CYP3A4, CYP2C9), which may alter the metabolism and blood levels of certain prescription medications, including cyclosporine, some fluoroquinolone antibiotics, and calcium channel blockers. High doses in animal studies have occasionally shown signs of renal toxicity, though this has not been replicated in human data at standard supplemental doses. Mild gastrointestinal discomfort, including nausea and headache, has been reported in some trials. Individuals on anticoagulant or antiplatelet therapy should be aware that quercetin has mild antiplatelet properties that could theoretically compound bleeding risk.